FDA Backchannel: Biogen's Hidden Meetings to Push Aduhelm

A joint congressional investigation has exposed unprecedented collusion between the FDA and Biogen to push through the controversial Alzheimer's drug Aduhelm. Internal communications and whistleblower testimonies reveal that FDA officials and Biogen executives engaged in dozens of undocumented "off-the-books" meetings, systematically circumventing standard scientific review protocols. Despite the FDA's own independent advisory committee overwhelmingly rejecting the drug due to contradictory clinical trial data—which showed zero efficacy in one of the two major studies—the agency utilized the "accelerated approval" loophole to greenlight the medication. Intelligence from within the regulatory body indicates this pathway is being increasingly exploited by Big Pharma to monetize failed pipeline assets without rigorous proof of clinical benefit. The approval set a dangerous precedent, allowing unproven, high-cost therapies—initially priced at $56,000 annually—into the US market while actively suppressing negative trial data. This signals a profound systemic compromise within American drug regulation, prioritizing corporate revenue streams and stock valuations over patient safety and scientific integrity.